LEAP-010
14 Dec 2020
LEAP-010
NCT04199104
A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
Merck Sharp & Dohme Corp.
Cancer Type | Head and Neck |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | Metastatic or Widespread, Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2020-02-05 |
Anticipated End Date | 2024-04-24 |
Hospital | Royal Adelaide Hospital |
---|---|
Clinical Trial Coordinator | Anne Milton |
anne.milton@sa.gov.au | |
Phone | 08 7074 2342 |
Principal Investigator | Dr Anne Taylor |
Recruitment Status | Recruiting |